Ammad Ahmad Farooqi, Syed M Kamran Majeed, Qaisar Mansoor, Muhammad Ismail
{"title":"Population-specific genetic variation at microRNA-629-binding site in the 3'-UTR of NBS1 gene in prostate cancer patients.","authors":"Ammad Ahmad Farooqi, Syed M Kamran Majeed, Qaisar Mansoor, Muhammad Ismail","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Prostate cancer is a genomically complex disease and recently emerging scientific evidence is adding new pieces of information into existing pool of knowledge of oncology. Prostate cancer cells tactfully rewire signaling cascades in presence or absence of androgen. We do not have finer proteome and genome based patient related information of our cancer patients.</p><p><strong>Methodology: </strong>In the present laboratory research, we studied 3' UTR C/T and A/G polymorphism in NBS1 gene in 100 prostate cancer patients and 100 healthy individuals without any previous clinical history, using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis.</p><p><strong>Results: </strong>For rs13312986 A&#62;G genotypes, AA was 78% in patients and 80% in controls. AG was 21% in patients and 20% in controls. GG was 1% in patients and none was detected in control. Allelic frequencies for A was 0.885% in patients and 0.9% in controls. Allelic frequencies for G were 0.115% in patients and 0.1% in controls. For rs14448 T&#62;C genotypes, TC was 23% in patients and 20% in controls. TT was 77% in patients and 80% in controls. CC was not detected either in patients or controls. T allele was 0.885% in patients and 0.9% in controls. C allele was 0.115% in patients and 0.1%-+ in controls.</p><p><strong>Conclusions: </strong>Future studies must converge on deeper and detailed mechanisms, as miRNA regulation of NBS1 is incompletely studied and exploration of these connections constitutes one of the most exciting areas in clinical oncology.</p>","PeriodicalId":45335,"journal":{"name":"Journal of Experimental Therapeutics and Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Experimental Therapeutics and Oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Prostate cancer is a genomically complex disease and recently emerging scientific evidence is adding new pieces of information into existing pool of knowledge of oncology. Prostate cancer cells tactfully rewire signaling cascades in presence or absence of androgen. We do not have finer proteome and genome based patient related information of our cancer patients.
Methodology: In the present laboratory research, we studied 3' UTR C/T and A/G polymorphism in NBS1 gene in 100 prostate cancer patients and 100 healthy individuals without any previous clinical history, using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis.
Results: For rs13312986 A>G genotypes, AA was 78% in patients and 80% in controls. AG was 21% in patients and 20% in controls. GG was 1% in patients and none was detected in control. Allelic frequencies for A was 0.885% in patients and 0.9% in controls. Allelic frequencies for G were 0.115% in patients and 0.1% in controls. For rs14448 T>C genotypes, TC was 23% in patients and 20% in controls. TT was 77% in patients and 80% in controls. CC was not detected either in patients or controls. T allele was 0.885% in patients and 0.9% in controls. C allele was 0.115% in patients and 0.1%-+ in controls.
Conclusions: Future studies must converge on deeper and detailed mechanisms, as miRNA regulation of NBS1 is incompletely studied and exploration of these connections constitutes one of the most exciting areas in clinical oncology.